Multi-omics in Unresolved HBOC

> Research explainer: This briefing examines verified primary research published 56 days before the briefing date. It is not a same-day research update and does not provide medical advice.

Evidence

The study examined 134 high-risk people with breast cancer and/or ovarian cancer who were being evaluated for suspected hereditary breast and ovarian cancer (HBOC). It used whole-genome sequencing for all 134 participants, with whole-transcriptome sequencing available for 103 and optical genome mapping for 105; 74 had data from all three platforms. [pmid:42380125]

This was a selected rather than population-representative cohort. Most participants were of Central-Northern European ancestry (125 of 134), while nine had other ancestry; 129 were biologically female and five biologically male. The source describes the work as focused on unresolved HBOC cases and notes that routine testing can leave many clinically eligible patients without pathogenic or likely pathogenic variants in diagnostically consented core genes. [pmid:42380125]

Across the cohort, the investigators reported likely pathogenic or pathogenic variants in DNA-repair genes in 18 patients. The reported findings included variants in several RECQ helicase and other DNA-repair genes, an intragenic deletion in FANCM, and six rare mobile-element insertions in DNA-repair genes. The supplied material characterizes these as candidate susceptibility factors, rather than as established HBOC susceptibility factors. [pmid:42380125]

The study also evaluated BRIDGES_306, described in the source as PRS306, in 75 women. Incorporating the score shifted estimated lifetime breast-cancer risk by at least five percentage points, in both upward and downward directions. These shifts included some carriers of rare DNA-repair-gene variants. [pmid:42380125]

Analysis — Multi-omics in unresolved cases

The central contribution is methodological: the study combines assays that interrogate different types of variation. Whole-genome sequencing can provide a broad variant search, whole-transcriptome sequencing supplies transcript-level information, optical genome mapping is used to characterize structural variation, and specialized analysis is used for mobile-element insertions. In this selected cohort, that combination yielded candidate findings beyond routine core-gene testing. [pmid:42380125]

The results also frame inherited susceptibility as potentially heterogeneous. Eighteen reported DNA-repair-gene findings, one intragenic FANCM deletion, and six rare mobile-element insertions indicate that the authors’ search extended beyond small variants in conventional testing targets. That broadening is useful for hypothesis generation in unresolved cases, but the source does not show that each reported factor confers HBOC risk or should be treated as clinically actionable. [pmid:42380125]

PRS306 adds a separate layer of estimated risk rather than identifying a single rare variant. The reported five-percentage-point-or-greater shifts among 75 women show that a polygenic score can change modelled lifetime-risk estimates in this dataset, including for some rare-variant carriers. The upward and downward shifts matter analytically because they show re-estimation in both directions; they do not demonstrate better outcomes, improved prediction in other populations, or a management benefit. [pmid:42380125]

Limitations

The supplied abstract and excerpt do not establish clinical validity for the candidate genes, the FANCM deletion, or the mobile-element insertions. They also do not establish causality, population-level risk estimates, or clinical management benefit. [pmid:42380125]

Generalizability is constrained by the small, highly selected cohort and its ancestry distribution: 125 of 134 participants were of Central-Northern European ancestry. The source further notes that breast-cancer polygenic risk scores have predominantly been developed and validated in populations of European ancestry, which is relevant when interpreting PRS306 estimates outside the represented population. [pmid:42380125]

PRS306 results were available for only 75 women and were reported as estimated lifetime-risk shifts. The supplied material does not demonstrate improved prediction or patient outcomes from those shifts. Finally, the excerpt ends before the full methods and results are available, limiting assessment of variant classification, validation procedures, statistical significance, and follow-up. [pmid:42380125]

Evidence boundary

This one-source briefing is limited to what the cited study reports. It does not establish independent confirmation, broader clinical effectiveness, or patient-specific guidance. The design, population, measurements, and follow-up described in that source define the evidence boundary. This summary provides research context and is not medical advice. The evidence should be read as a bounded report of the study rather than as a conclusion about other populations, settings, interventions, or outcomes. Any possible connection to disease mechanisms remains limited to the measurements and interpretations documented by the cited authors. Terms describing associations, responses, or biological patterns retain the meaning and uncertainty given in that source.

No inference beyond the cited source is made here.